Product image of Xofigo (Radium Ra 223 Dichloride) supplied by GNH India

Xofigo

Active Ingredient:
Radium Ra 223 Dichloride
Origin:
EU

Xofigo (Radium Ra 223 Dichloride)

Xofigo (Radium Ra 223 Dichloride) is a radiopharmaceutical used for targeted alpha therapy in certain cancers. Administered via intravenous infusion, it helps manage symptoms in advanced prostate cancer. Suitable for patients with symptomatic bone metastases. Always consult a healthcare provider for suitability.

Manufacturer / TM Owner

Bayer Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Xofigo is primarily used to treat adults with castration-resistant prostate cancer that has spread to the bones. It targets cancer cells in the bones with alpha particles, helping to reduce pain and slow disease progression. This therapy is often considered when other treatments are no longer effective. It is not a cure but aims to improve quality of life.

Side Effects

  • Patients receiving Xofigo may experience a reduction in bone pain and fewer complications from bone metastases. The treatment works by emitting alpha radiation that targets cancerous bone areas while minimizing damage to healthy tissue. Some may notice improved mobility or reduced need for pain medication over time.

Precautions & Warnings

  • Xofigo should only be handled and administered by trained healthcare professionals in a controlled setting. Patients may need to avoid close contact with others for a short period after treatment due to radiation exposure. Hydration and regular monitoring are typically recommended during therapy.

Avoid Interactions

  • No significant drug interactions have been established with Xofigo, but caution is advised when combining with other systemic cancer therapies. Radiation exposure from Xofigo may accumulate with other radiopharmaceuticals or external beam radiation. Always inform your doctor about all medications and treatments being used.

Frequently Asked Questions

Xofigo is used to treat adults with advanced prostate cancer that has spread to the bones.

Xofigo is given as an intravenous infusion by a healthcare professional in a clinical setting.

Xofigo is not a cure but may help reduce bone pain and slow disease progression.

Common effects may include nausea, diarrhea, and temporary bone marrow suppression.

Travel restrictions may apply immediately after treatment due to radiation precautions; consult your doctor.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Radium Ra 223 Dichloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT